CDX2 and non-small cell lung carcinoma: As for the VDR rs11568820 (Cdx2) SNP, a clinical trial in 155 Asian patients (from Japan) diagnosed with NSCLC showed that individuals carrying the VDR rs11568820 (Cdx2)-TT/CT genotypes showed higher OS after 5 years (p = 0.040, HR = 0.41, 95% CI = 0.18–0.97; TT/CT vs. CC) [36].